Evidence map›Paper›PMID 31186529›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019

Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.

Dana Balitzer, Nancy M Joseph, Linda Ferrell, Nafis Shafizadeh, Dhanpat Jain, Xuchen Zhang, Matthew Yeh, Luca di Tommaso, Sanjay Kakar

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Cholangiocarcinoma.Nature reviews. Disease primers · 2021
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Frontiers in oncology · 2021
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Dana BalitzerDepartment of Pathology, University of California, San Francisco, CA, USA.
Nancy M JosephDepartment of Pathology, University of California, San Francisco, CA, USA.
Linda FerrellDepartment of Pathology, University of California, San Francisco, CA, USA.
Nafis ShafizadehDepartment of Pathology, Kaiser Permanente Woodland Hills Medical Center, Woodland Hills, CA, USA.
Dhanpat JainDepartment of Pathology, Yale New Haven Hospital, New Haven, CT, USA.
Xuchen ZhangDepartment of Pathology, Yale New Haven Hospital, New Haven, CT, USA.
Matthew YehDepartment of Pathology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-7430-2939
Luca di TommasoDepartment of Pathology, Humanitas Clinical and Research Center, Rozzano-IRCCS, and Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
Sanjay KakarDepartment of Pathology, University of California, San Francisco, CA, USA. sanjay.kakar@ucsf.edu.
University of California, San Francisco · USYale New Haven Hospital · USHumanitas University · ITKaiser Permanente · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholangiolocellular carcinoma is characterized by low grade cytologic atypia, and anastomosing cords and glands resembling cholangioles or canals of Hering. Cholangiolocellular carcinoma has been variously regarded as a subtype of intrahepatic cholangiocarcinoma (World Health Organization 2000), combined hepatocellular-cholangiocarcinoma of stem cell subtype (World Health Organization 2010) and a distinct type of primary liver carcinoma. Capture-based next generation sequencing targeting the coding regions of 479 cancer genes and select introns was performed on 17 cases (5 cholangiolocellular carcinomas, 7 intrahepatic cholangiocarcinomas, 5 mixed cholangiolocellular-intrahepatic cholangiocarcinomas) along with immunohistochemistry for CK19, SALL4, CD56, CD117, and EMA. For 5 mixed cholangiolocellular-intrahepatic cholangiocarcinoma, the individual areas were micro-dissected prior to sequencing. CK19 and EMA were positive in all cases; both luminal and cytoplasmic EMA was seen in 3/5 cholangiolocellular carcinoma and 3/6 intrahepatic cholangiocarcinomas. CD117 and SALL4 were negative in all cases. CD56 was positive in 2/5 cholangiolocellular carcinoma, 4/6 intrahepatic cholangiocarcinoma and 2/5 mixed cases. Mutations typical of intrahepatic cholangiocarcinoma (IDH1/2, PBRM1, FGFR2) were present in 90% of cases with cholangiolocellular carcinoma component. The genomic profile (IDH1/2 mutations, FGFR2 fusions, chromatin-remodeling gene mutations such as ARID1A, PBRM1) and copy number alterations were similar in cholangiolocellular carcinoma, intrahepatic cholangiocarcinoma and mixed cholangiolocellular-intrahepatic cholangiocarcinoma. In all mixed cases, the immunohistochemistry results, mutational profile and copy number alterations in both components were similar. Cholangiolocellular carcinoma should be categorized as a histologic subtype of well-differentiated intrahepatic cholangiocarcinoma, and should not be considered a distinct entity, or combined hepatocellular-cholangiocarcinoma unless a distinct hepatocellular component is also present.

Indexed as

AdultAgedBile Duct NeoplasmsBile Ducts, IntrahepaticBiomarkers, TumorCholangiocarcinomaDNA-Binding ProteinsFemaleHigh-Throughput Nucleotide SequencingHumansImmunohistochemistryLiver NeoplasmsMaleMiddle AgedMutationReceptor, Fibroblast Growth Factor, Type 2ARID1A protein, humanBiomarkers, TumorDNA-Binding ProteinsFGFR2 protein, humanPBRM1 protein, humanReceptor, Fibroblast Growth Factor, Type 2Transcription Factors

Identifiers

PMID31186529
OpenAlexW2952464140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.